COVAXX has struck an exclusive COVID-19 vaccine partnership with India’s Aurobindo Pharma.
The agreement will see US firm COVAXX expand its global development and commercialization of UB-612 – a multitope peptide-based vaccine to fight COVID-19 – to India and the United Nations Children’s Fund (UNICEF) agency.
“COVAXX is committed to providing an equitable distribution of UB-612 vaccine by prioritizing markets where the unmet need is greatest,” said Mei Mei Hu, co-founder and CEO of COVAXX.
“During this global health crisis response, we must establish partners with the strongest capabilities, like Aurobindo, to expand the manufacturing and delivery of our vaccine.
“As one of the leading industry players with a strong track record of execution and investment in vaccines, Aurobindo Pharma is the ideal partner to advance UB-612 in India and other emerging nations and to support our mission of democratizing health worldwide.”
Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612.
Under the signed license agreement, Aurobindo Pharma has obtained the exclusive rights to commercialize in India and to UNICEF and non-exclusive rights in other select emerging and developing markets. COVAXX will supply the bulk product and Aurobindo will manufacture the finished doses at its facilities in Hyderabad, India.
Aurobindo has an initial capacity of 220 million doses in multi-dose presentation and is building additional facilities to increase its capacity to have nearly 480 million doses manufactured by June 2021.
The financial terms of the agreement are not disclosed.